Compare CL & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CL | ZTS |
|---|---|---|
| Founded | 1806 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0B | 53.9B |
| IPO Year | N/A | 2013 |
| Metric | CL | ZTS |
|---|---|---|
| Price | $79.77 | $126.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 11 |
| Target Price | $90.47 | ★ $174.60 |
| AVG Volume (30 Days) | 6.0M | ★ 6.1M |
| Earning Date | 01-30-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.61% | 1.68% |
| EPS Growth | 2.56 | ★ 11.64 |
| EPS | 3.57 | ★ 5.94 |
| Revenue | ★ $20,097,000,000.00 | $9,397,000,000.00 |
| Revenue This Year | $3.88 | $3.04 |
| Revenue Next Year | $3.33 | $4.98 |
| P/E Ratio | $22.33 | ★ $21.26 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $74.55 | $115.25 |
| 52 Week High | $100.18 | $177.40 |
| Indicator | CL | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.40 | 57.01 |
| Support Level | $77.77 | $121.12 |
| Resistance Level | $80.40 | $125.53 |
| Average True Range (ATR) | 1.30 | 2.71 |
| MACD | 0.20 | 1.15 |
| Stochastic Oscillator | 85.82 | 99.67 |
Since its founding in 1806, Colgate-Palmolive has grown into a leading player in the household and personal care industry. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and home care products sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one-fifth of sales), which sells a majority of its products through veterinarians and specialty pet retailers.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.